Flow Traders U.S.’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Flow Traders U.S.’s Portfolio SABSW Stock Details SABSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,938	Closed	-$1K	–	1071
2023 Q1	$1K	Sell	15,938 -75	-0.5%	-$4	﹤0.01%	836
2022 Q4	$1K	Buy	16,013 +4,274	+36%	+$261	﹤0.01%	749
2022 Q3	$1K	Buy	+11,739	New	+$1.4K	﹤0.01%	908

Other funds holding SABSW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Flow Traders U.S.'s SABSW Position: Q2 2023 in Review

Flow Traders U.S. sold out of SAB Biotherapeutics Warrant (SABSW) in Q2 2023, closing a stake of 15,938 shares — an estimated $1K sold.

Flow Traders U.S. first reported a position in SABSW in Q3 2022 and held it in 3 quarters. The position peaked at $1K in Q1 2023. 10 funds tracked by Wall St. Rank hold SABSW as of Q2 2023.

Flow Traders U.S. reported no remaining SAB Biotherapeutics Warrant position as of Q2 2023 after selling out during the quarter.
Flow Traders U.S. sold 15,938 SAB Biotherapeutics Warrant shares in Q2 2023, an estimated $1K.
Flow Traders U.S. first reported a position in SAB Biotherapeutics Warrant in Q3 2022 and held it in 3 quarters.
Flow Traders U.S.'s SAB Biotherapeutics Warrant position peaked at $1K in Q1 2023.
10 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q2 2023.

Based on Flow Traders U.S.'s 13F filing for Q2 2023, filed 9 Aug 2023.